Глиоксилат айналымы: биохимиялық реакциялар тізбегі мен эволюциялық дамуы

Series of interconnected biochemical reactions

The glyoxylate cycle, a variation of the tricarboxylic acid cycle, is an anabolic pathway occurring in plants, bacteria, protists, and fungi. The glyoxylate cycle centers on the conversion of acetyl CoA to succinate for the synthesis of carbohydrates. In microorganisms, the glyoxylate cycle allows cells to use two carbons (C2 compounds), such as acetate, to satisfy cellular carbon requirements when simple sugars such as glucose or fructose are not available. The cycle is generally assumed to be absent in animals, with the exception of nematodes at the early stages of embryogenesis. In recent years, however, the detection of malate synthase (MS) and isocitrate lyase (ICL), key enzymes involved in the glyoxylate cycle, in some animal tissue has raised questions regarding the evolutionary relationship of enzymes in bacteria and animals and suggests that animals encode alternative enzymes of the cycle that differ in function from known MS and ICL in non metazoan species. Plants as well as some algae and bacteria can use acetate as the carbon source for the production of carbon compounds. Plants and bacteria employ a modification of the TCA cycle called the glyoxylate cycle to produce four carbon dicarboxylic acid from two carbon acetate units. The glyoxylate cycle bypasses the two oxidative decarboxylation reactions of the TCA cycle and directly converts isocitrate through isocitrate lyase and malate synthase into malate and succinate. The glyoxylate cycle was discovered in 1957 at the University of Oxford by Sir Hans Kornberg and his mentor Hans Krebs, resulting in a Nature paper Synthesis of Cell Constituents from C2 Units by a Modified Tricarboxylic Acid Cycle.

The glyoxylate cycle uses five of the eight enzymes associated with the tricarboxylic acid cycle: citrate synthase, aconitase, succinate dehydrogenase, fumarase, and malate dehydrogenase. The two cycles differ in that in the glyoxylate cycle, isocitrate is converted into glyoxylate and succinate by isocitrate lyase (ICL) instead of into α ketoglutarate.

The glyoxylate cycle may serve an entirely different purpose in some species of pathogenic fungi. The levels of the main enzymes of the glyoxylate cycle, ICL and MS, are greatly increased upon contact with a human host. Mutants of a particular species of fungi that lacked ICL were also significantly less virulent in studies with mice compared to the wild type. The exact link between these two observations is still being explored, but it can be concluded that the glyoxylate cycle is a significant factor in the pathogenesis of these microbes.

Vertebrates were once thought to be unable to perform this cycle because there was no evidence of its two key enzymes, isocitrate lyase and malate synthase. However, some research suggests that this pathway may exist in some, if not all, vertebrates. Specifically, some studies show evidence of components of the glyoxylate cycle existing in significant amounts in the liver tissue of chickens. Data such as these support the idea that the cycle could theoretically occur in even the most complex vertebrates. Other experiments have also provided evidence that the cycle is present among certain insect and marine invertebrate species, as well as strong evidence of the cycle's presence in nematode species. However, other experiments refute this claim. Some publications conflict on the presence of the cycle in mammals: for example, one paper has stated that the glyoxylate cycle is active in hibernating bears, but this report was disputed in a later paper. Evidence exists for malate synthase activity in humans due to a dual functional malate/B methylmalate synthase of mitochondrial origin called CLYBL expressed in brown fat and kidney. Vitamin D may regulate this pathway in vertebrates.

Due to the central role of the glyoxylate cycle in the metabolism of pathogenic species including fungi and bacteria, enzymes of the glyoxylate cycle are current inhibition targets for the treatment of diseases. Most reported inhibitors of the glyoxylate cycle target the first enzyme of the cycle (ICL). Inhibitors were reported for Candida albicans for potential use as antifungal agents. The mycobacterial glyoxylate cycle is also being targeted for potential treatments of tuberculosis.

The prospect of engineering various metabolic pathways into mammals which do not possess them is a topic of great interest for bio engineers today. The glyoxylate cycle is one of the pathways which engineers have attempted to manipulate into mammalian cells. This is primarily of interest for engineers in order to increase the production of wool in sheep, which is limited by the access to stores of glucose. By introducing the pathway into sheep, the large stores of acetate in cells could be used in order to synthesize glucose through the cycle, allowing for increased production of wool. Mammals are incapable of executing the pathway due to the lack of two enzymes, isocitrate lyase and malate synthase, which are needed in order for the cycle to take place. It is believed by some that the genes to produce these enzymes, however, are pseudogenic in mammals, meaning that the gene is not necessarily absent, rather, it is merely "turned off". Efforts to engineer the pathway into more complex animals, such as sheep, have not been effective. This illustrates that much more research needs to be done on the topic, and suggests it is possible that a high expression of the cycle in animals would not be tolerated by the chemistry of the cell. Incorporating the cycle into mammals will benefit from advances in nuclear transfer technology, which will enable engineers to examine and access the pathway for functional integration within the genome before its transfer to animals. There are possible benefits, however, to the cycle's absence in mammalian cells. The cycle is present in microorganisms that cause disease but is absent in mammals, for example humans. There is a strong plausibility of the development of antibiotics that would attack the glyoxylate cycle, which would kill the disease causing microorganisms that depend on the cycle for their survival, yet would not harm humans where the cycle, and thus the enzymes that the antibiotic would target, are absent.